で公開中です！ 詳しく見る
NTBLのアイコン

Notable Labs, Ltd. Ordinary Shares
NTBL

上場廃止済み

NTBLは2024年10月22日に上場廃止となりました。

ランキングに戻る
 

概要： Notable Labs Ltd is a clinical-stage platform therapeutics company developing predictive precision medicines for patients with cancer. Through its proprietary Predictive Precision Medicines Platform (PPMP), Notable bio-simulates a cancer treatment to predict whether or not a patient is likely to respond to that specific therapeutic. PPMP is designed to enable Notable to identify and select patients expected to be clinically responsive before the initiation of their treatment and potentially enable fast-track therapeutic development in this patient population.

従業員数： 16

ヘルスケア 医薬品メーカー（総合）

ニュース

ポジティブ
ニュートラル
ネガティブ
センチメント 3か月間
ポジティブ 0%
ニュートラル 0%
ネガティブ 0%
ニュートラル
GlobeNewsWire
2 年前
Notable Labs to Present Data on September 4th at SOHO 2024
Society of Hematologic Oncology (SOHO) session to highlight volasertib program Phase 2 volasertib AML program expected to begin in the coming months FOSTER CITY, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd.
Notable Labs to Present Data on September 4th at SOHO 2024
ニュートラル
GlobeNewsWire
2 年前
Notable Labs Announces CEO Transition
Thomas Bock, MD resigns as CEO; Joseph Wagner, PhD, CSO, appointed interim CEO Company affirms plan to initiate volasertib Phase 2 program in the coming months FOSTER CITY, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd.
Notable Labs Announces CEO Transition
ニュートラル
GlobeNewsWire
2 年前
Notable Labs Receives FDA Clearance to Proceed Further with Volasertib Phase 2 Study
Phase 2 dosing plan, agreed with FDA, paves the way to initiate patient enrollment Phase 2 dosing plan, agreed with FDA, paves the way to initiate patient enrollment
Notable Labs Receives FDA Clearance to Proceed Further with Volasertib Phase 2 Study
ネガティブ
Zacks Investment Research
2 年前
Bears are Losing Control Over Notable Labs (NTBL), Here's Why It's a 'Buy' Now
Notable Labs (NTBL) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
ニュートラル
GlobeNewsWire
2 年前
Notable Labs to Participate in Fireside Chat at the Citizens JMP Securities Life Sciences Conference 2024
FOSTER CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable”, “Notable Labs” or the “Company”), a clinical-stage precision oncology company developing new cancer therapies identified by its Predictive Medicine Platform (PMP), today announced that Thomas Bock, M.D., Chief Executive Officer of Notable Labs, will participate in a fireside chat at the Citizens JMP Securities Life Sciences Conference 2024, taking place on May 13-14, 2024, in New York City.
Notable Labs to Participate in Fireside Chat at the Citizens JMP Securities Life Sciences Conference 2024
ポジティブ
Zacks Investment Research
2 年前
Notable Labs (NTBL) Upgraded to Buy: What Does It Mean for the Stock?
Notable Labs (NTBL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
ニュートラル
GlobeNewsWire
2 年前
Notable Labs Reports 2023 Financial Results and Provides a Business Update
FOSTER CITY, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable” or the “Company”), a clinical-stage precision oncology company developing new cancer therapies identified by its Predictive Precision Medicine Platform (PPMP), reported financial results for the year ended December 31, 2023 and provided a business update.
Notable Labs Reports 2023 Financial Results and Provides a Business Update
ニュートラル
GlobeNewsWire
2 年前
Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024
FOSTER CITY, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable” or the “Company”), a clinical-stage precision oncology company developing a new class of cancer therapies identified by its Predictive Precision Medicine Platform (PPMP), today presented the design for the PPMP-enabled Phase 2 trial with volasertib, in combination with decitabine, in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) at the American Association for Cancer Research (AACR 2024) being held in San Diego, CA (Poster abstract 5178).
Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024
ニュートラル
GlobeNewsWire
2 年前
Notable Labs Presentation of Data Related to Innovations in the Use of Cryopreserved Samples in the PPMP Assay at AACR 2024 Expands the Potential of the Platform
FOSTER CITY, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable” or the “Company”), a clinical-stage precision oncology company developing a new class of cancer therapies identified by its Predictive Precision Medicine Platform (PPMP), today presented data related to innovations in the use of cryopreserved samples in the PPMP assay at the American Association for Cancer Research (AACR 2024) being held in San Diego, CA (Poster abstract 2548).
Notable Labs Presentation of Data Related to Innovations in the Use of Cryopreserved Samples in the PPMP Assay at AACR 2024 Expands the Potential of the Platform
ニュートラル
GlobeNewsWire
2 年前
Notable Labs to Present Two Posters at AACR 2024 on PPMP Platform
FOSTER CITY, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable”, “Notable Labs”), a clinical-stage therapeutics platform company developing a new class of cancer therapies based on its Predictive Precision Medicine Platform (PPMP), today announced that the Company will present two posters related to its PPMP platform at the American Association for Cancer Research Annual Meeting 2024 (AACR 2024), taking place April 5-10, 2024 in San Diego, CA.
Notable Labs to Present Two Posters at AACR 2024 on PPMP Platform
ニュースランキングを見る
価格チャートは Lightweight Charts™ を使用して実装されています